Triple negative breast cancer (TNBC) accounts for approximately 10%–15% of all breast cancers and is characterized by a lack of expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)3. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.